Cyclerion Therapeutics, Inc. announced that on and effective September 30, 2022, Andreas Busch, Ph.D. resigned from his position as Chief Scientific Officer of Cyclerion Therapeutics, Inc. (the Company) to pursue another opportunity. Dr. Busch did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.93 USD | -3.62% | -16.29% | -12.54% |
Mar. 05 | Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Cyclerion Therapeutics, Inc. Appoints Regina Graul as President | CI |
1st Jan change | Capi. | |
---|---|---|
-12.54% | 7.44M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CYCN Stock
- News Cyclerion Therapeutics, Inc.
- Cyclerion Therapeutics, Inc. Announces Resignation of Andreas Busch as Chief Scientific Officer